SCHEDULE: SilverArc Capital Management Reports Stake in Cellectar Biosciences

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 9.99% of Cellectar Biosciences Inc.'s Class A Common Stock, primarily through exercisable warrants.

Summary

• SilverArc Capital Management, LLC and Devesh Gandhi (collectively, the "Reporting Persons") have filed a Schedule 13G.
• They report beneficial ownership of 851,285 shares of Cellectar Biosciences Inc. Class A Common Stock, representing 9.99% of the class.
• This ownership is primarily held through exercisable warrants, with a blocker provision limiting exercise if it exceeds 9.99% beneficial ownership.
• The filing indicates that SilverArc Capital Management, LLC accounts, specifically SilverArc Capital Alpha Fund I, LP and SilverArc Capital Alpha Fund II, LP, own 321,728 shares and 1,132,074 exercisable warrants.
• The percentage calculations are based on the Issuer's Schedule 14A filed on May 28th, 2026, which stated 7,991,812 shares of Common Stock outstanding, assuming warrant exercise subject to the 9.99% limit.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new financial or strategic information.

Positives

• Reporting Persons hold a significant stake (9.99%) in Cellectar Biosciences Inc., indicating investor confidence.
• The ownership is structured to comply with beneficial ownership limits, demonstrating adherence to regulatory requirements.

Negatives

• The filing does not provide new financial performance data or strategic updates for Cellectar Biosciences Inc.
• The significant portion of ownership is in exercisable warrants, which are contingent on future events and subject to a 9.99% ownership cap.

Risks

• The value and control associated with the warrants are subject to the 9.99% beneficial ownership limitation, which could restrict future actions.
• The filing does not offer insights into the underlying performance or future prospects of Cellectar Biosciences Inc., leaving potential investors to conduct their own due diligence.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Cellectar Biosciences Inc. The future outlook for the Reporting Persons' stake is contingent on the exercise of warrants and compliance with ownership limits.

Management Comments

• "The Warrants may not be exercised if such exercise would cause the holder, together with its affiliates, to beneficially own in excess of 9.99% of the number of shares of the Issuer's Common Stock then outstanding."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates SilverArc Capital Management's strategic interest in Cellectar Biosciences, potentially positioning them for future influence or investment opportunities.

Stakeholder Impact

• Shareholders: The increased stake by SilverArc Capital Management may signal investor confidence or potential future activism, which could influence share price.
• Management: The filing may prompt management to engage with SilverArc Capital Management regarding their intentions and strategy.

Next Steps

• The Reporting Persons may exercise their warrants, subject to the 9.99% ownership limitation.
• Further actions by the Reporting Persons would depend on their investment strategy and the performance of Cellectar Biosciences Inc.

Key Dates

Keywords

Cellectar Biosciences, SilverArc Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Management